unknown
Stage
1
Investors
About
Develops antisense oligonucleotide (ASO) therapeutics that selectively upregulate gene expression by modulating regulatory RNA to address diseases caused by inadequate protein levels.
Explore CAMP4 Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.